Be the first person to write a business review for Millennium Pharmaceuticals, Inc.

MY Medicare wants to help with your medical care. Mingyuan Medicare Development, or MY Medicare, makes medical diagnostic products for the Chinese market. Its HealthDigit subsidiary produces biochips that detect certain proteins in the body and are used to diagnose and monitor cancer as well as track treatment efficacy. The company has agreements with major Chinese insurance companies, including Taiping Life, China Life, and Ping An Life, that use the chips in medical checkups. MY Medicare also makes a testing kit used to detect cervical cancer. It offers consultation for clinical and technical research and conducts training and seminars from research centers and plants in Shanghai and Beijing.

Mirus Bio provides gene transfer technologies to the pharmaceutical industry. The company's reagent kits assist researchers with in vitro transfection, in vivo delivery, DNA and RNA labeling, and RNA interference. Besides its kits, Mirus Bio is also developing its own therapies based on its intravenous technology, called Pathway IV, that facilitates the delivery of plasmid DNA to targeted muscles. One of those therapies is MyoDys, a gene therapy designed to treat muscular dystrophy by delaying loss of muscle function. Mirus Bio is also developing treatments for peripheral ischemia and anemia. Mirus Bio has agreed to be acquired by Roche Holding for $125 million.

Molecular Insight Pharmaceuticals was founded in 1997 and is based in Cambridge, Massachusetts. Molecular Insight Pharmaceuticals, Inc., a development stage biopharmaceutical company, engages in the research, development, and commercialization of molecular imaging pharmaceuticals and radiotherapeutics primarily in the areas of oncology and cardiology in the United States. The company develops Zemiva, a molecular imaging pharmaceutical product, which completed Phase II clinical trail for the diagnosis of cardiac ischemia or insufficient blood flow to the heart; and Trofex, a preclinical trail product for the detection of metastatic prostate cancer. Its molecular radiotherapeutic oncology product candidates under development include Azedra that completed Phase I clinical trail for the treatment of pheochromocytoma in adults and neuroblastoma in children; Onalta, a Phase II clinical trail product for the treatment of metastatic carcinoid and pancreatic neuroendocrine tumors; and Solazed, a preclinical trail product for the treatment of malignant metastatic melanoma. The company was formerly known as Biostream, Inc. and changed its name to Molecular Insight Pharmaceuticals, Inc. in 2003.

Momenta Pharmaceuticals was founded in 2001 and is based in Cambridge, Massachusetts. Momenta Pharmaceuticals, Inc., a biotechnology company, specializes in the structural analysis of complex mixture drugs. The company applies its technology for the development of generic versions of complex drug products, as well as for the discovery and development of novel drugs. Its product candidates include M-Enoxaparin, a generic version of Lovenox that is used to prevent and treat deep vein thrombosis, and to support the treatment of acute coronary syndromes; M356, a technology-enabled generic version of Copaxone, which is used for the reduction of the frequency of relapses in patients with relapse-remitting multiple sclerosis; and M118, an anticoagulant. The company also involves in developing generic or biosimilar glycoprotein products. Momenta Pharmaceuticals has collaborations with Sandoz AG and Sandoz Inc. to develop and commercialize injectable enoxaparin. The company was formerly known as Mimeon, Inc. and changed its name to Momenta Pharmaceuticals, Inc. in September 2002.

MorphoSys is a biotechnology firm with a human touch. Using its proprietary HuCAL catalog of fully human antibodies, the company is helping the world's largest drug firms develop human antibody therapies for a wide range of diseases. It helps its pharmaceutical clients in a number of ways: one, by installing its HuCAL library and related technology at customer sites in return for licensing fees; and second, by working in partnership with drug firms to develop potential antibody therapies. Its client list is a Who's Who of Big Pharma and includes Novartis, Pfizer, Roche, and Merck. MorphoSys also makes human antibodies (under the brand name AbD-Serotec) and sells them to researchers.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.